Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia

Biological Psychiatry

Volumn 57, Issue 4, 2005, Pages 399-405

  Smesny, Stefan ^a   Kinder, Daniel ^a   Willhardt, Ingo ^b   Rosburg, Timm ^a   Lasch, Jürgen ^b   Berger, Gregor ^c   Sauer, Heinrich ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c ORYGEN RESEARCH CENTRE   (Australia)

Author keywords

Early psychosis; First episode schizophrenia; iPLA2 activity; Lipid metabolism

Indexed keywords

NEUROLEPTIC AGENT; PHOSPHOLIPASE A2;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENZYME ACTIVITY; FEMALE; FLUOROMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; THIN LAYER CHROMATOGRAPHY;

EID: 13444291436     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.11.018     Document Type: Article

References (60)

1. M. Albers, H. Meurer, F. Marki, J. Klotz Phospholipase A2 activity in serum of neuroleptic-naive psychiatric inpatients Pharmacopsychiatry 26 1993 94 98
2. N.C. Andreasen The Scale for the Assessment of Negative Symptoms 1983 University of Iowa Iowa City
3. N.C. Andreasen The Scale for the Assessment of Positive Symptoms 1984 University of Iowa Iowa City
4. J. Balsinde, M.A. Balboa, P.A. Insel, E.A. Dennis Regulation and inhibition of phospholipase A2 Annu Rev Pharmacol Toxicol 39 1999 175 189
5. C.N. Bennett, D.F. Horrobin Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders An update Prostaglandins Leukot Essent Fatty Acids 63 2000 47 59
6. G.E. Berger, S. Wood, P.D. McGorry Incipient neurovulnerability and neuroprotection in early psychosis Psychopharmacol Bull 37 2003 79 101
7. G.E. Berger, S.J. Wood, C. Pantelis, D. Velakoulis, R.M. Wellard, P.D. McGorry Implications of lipid biology for the pathogenesis of schizophrenia Aust N Z J Psychiatry 36 2002 355 366
8. G. Calabrese, R.F. Deicken, G. Fein, E.L. Merrin, F. Schoenfeld, M.W. Weiner 31Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia Biol Psychiatry 32 1992 26 32
9. K.V. Chowdari, B. Brandstaetter, P. Semwal, T. Bhatia, S. Deshpande, R. Reddy, J. Wood Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples Psychiatr Genet 11 2001 207 212
10. E.A. Dennis Diversity of group types, regulation, and function of phospholipase A2 J Biol Chem 269 1994 13057 13060
11. A.B. Doris, K. Wahle, A. MacDonald, S. Morris, I. Coffey, W. Muir, D. Blackwood Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia Schizophr Res 31 1998 185 196
12. R.M. Frieboes, H.W. Moises, W.F. Gattaz, L. Yang, T. Li, X. Liu Lack of association between schizophrenia and the phospholipase-A(2) genes cPLA2 and sPLA2 Am J Med Genet 105 2001 246 249
13. T. Fujimoto, T. Nakano, T. Takano, Y. Hokazono, T. Asakura, T. Tsuji Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging Acta Psychiatr Scand 86 1992 455 462
14. H. Fukuzako, K. Takeuchi, K. Ueyama, T. Fukuzako, Y. Hokazono, K. Hirakawa 31P magnetic resonance spectroscopy of the medial temporal lobe of schizophrenic patients with neuroleptic-resistant marked positive symptoms Eur Arch Psychiatry Clin Neurosci 244 1994 236 240
15. W.F. Gattaz, J. Brunner Phospholipase A2 and the hypofrontality hypothesis of schizophrenia Prostaglandins Leukot Essent Fatty Acids 55 1996 109 113
16. W.F. Gattaz, C.V. Hubner, T.J. Nevalainen, T. Thuren, P.K. Kinnunen Increased serum phospholipase A2 activity in schizophrenia a replication study Biol Psychiatry 28 1990 495 501
17. W.F. Gattaz, M. Kollisch, T. Thuren, J.A. Virtanen, P.K. Kinnunen Increased plasma phospholipase-A2 activity in schizophrenic patients reduction after neuroleptic therapy Biol Psychiatry 22 1987 421 426
18. W.F. Gattaz, T.J. Nevalainen, P.K. Kinnunen Possible involvement of phospholipase A2 in the pathogenesis of schizophrenia Fortschr Neurol Psychiatr 58 1990 148 153
19. W.F. Gattaz, A. Schmitt, A. Maras Increased platelet phospholipase A2 activity in schizophrenia Schizophr Res 16 1995 1 6
20. D. Horrobin Prostaglandins and schizophrenia Further discussion of the evidence Psychol Med 8 1978 43 48
21. D.F. Horrobin The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia Schizophr Res 30 1998 193 208
22. D.F. Horrobin, A.I. Glen, C.J. Hudson Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders The relationship between dyslexia and schizophrenia Med Hypotheses 45 1995 605 613
23. D.F. Horrobin, A.I. Glen, K. Vaddadi The membrane hypothesis of schizophrenia Schizophr Res 13 1994 195 207
24. C. Hudson, A. Gotowiec, M. Seeman, J. Warsh, B.M. Ross Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia Biol Psychiatry 46 1999 401 405
25. C.J. Hudson, J.L. Kennedy, A. Gotowiec, A. Lin, N. King, K. Gojtan Genetic variant near cytosolic phospholipase A2 associated with schizophrenia Schizophr Res 21 1996 111 116
26. C.J. Hudson, L.T. Young, P.P. Li, J.J. Warsh CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia Synapse 13 1993 278 293
27. H. Katila, B. Appelberg, R. Rimon No differences in phospholipase-A2 activity between acute psychiatric patients and controls Schizophr Res 26 1997 103 105
28. T. Kato, T. Shioiri, J. Murashita, H. Hamakawa, T. Inubushi, S. Takahashi Phosphorus-31 magnetic resonance spectroscopy and ventricular enlargement in bipolar disorder Psychiatry Res 55 1994 41 50
29. M.S. Keshavan, J.W. Pettegrew, K. Panchalingam, D. Kaplan, J. Brar, K. Campbell In vivo 31P nuclear magnetic resonance (NMR) spectroscopy of the frontal lobe metabolism in neuroleptic naive first episode psychoses Schizophr Res 2 1989 122
30. M.S. Keshavan, J.W. Pettegrew, K.S. Panchalingam, D. Kaplan, E. Bozik Phosphorus 31 magnetic resonance spectroscopy detects altered brain metabolism before onset of schizophrenia Arch Gen Psychiatry 48 1991 1112 1113
31. M.S. Keshavan, J.A. Stanley, J.W. Pettegrew Magnetic resonance spectroscopy in schizophrenia Methodological issues and findings--part II Biol Psychiatry 48 2000 369 380
32. J. Lasch, I. Willhardt, D. Kinder, H. Sauer, S. Smesny Fluorometric assays of phospholipase A2 activity with three different substrates in biological samples of patients with schizophrenia Clin Chem Lab Med 41 2003 908 914
33. S.P. Mahadik, D.R. Evans Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications Psychiatr Clin North Am 26 2003 85 102
34. S. Mukerjee, S.P. Mahadik, R. Scheffer, E.E. Correnti, H. Kelkar Impaired antioxidant defense at the onset of psychosis Schizophr Res 19 1996 19 26
35. S. Nigam, T. Schewe Phospholipase A2s and lipid peroxidation Biochem Biophys Acta 1488 2000 167 181
36. M. Noponen, M. Sanfilipo, K. Samanich, H. Ryder, G. Ko, B. Angrist Elevated PLA2 activity in schizophrenics and other psychiatric patients Biol Psychiatry 34 1993 641 649
37. M. Peet, C.N. Ramchand, J. Lee, S.D. Telang, G.K. Vankar, S. Shah, J. Wei Association of the Ban I dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia Psychiatr Genet 8 1998 191 192
38. J.W. Pettegrew, M.S. Keshavan, K. Panchalingam, S. Strychor, D.B. Kaplan, M.G. Tretta, M. Allen Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy Arch Gen Psychiatry 48 1991 563 568
39. K.A. Pontus, L. Forsell, B.P. Kennedy, H.E. Claesson The human calcium-independent phospholipase A2 gene--multiple enzymes with distinct properties from a single gene Eur J Biochem 262 1999 575 585
40. J.J. Potwarka, D.J. Drost, P.C. Williamson, T. Carr, G. Canaran, W.J. Rylett, R.W. Neufeld A 1H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls Biol Psychiatry 45 1999 687 693
41. S.A. Price, H. Fox, D. St Clair, D.J. Shaw Lack of association between schizophrenia and a polymorphism close to the cytosolic phospholipase A2 gene Psychiatr Genet 7 1997 111 114
42. R. Reddy, M. Keshavan, J.K. Yao Reduced plasma antioxidants in first-episode patients with schizophrenia Schizophr Res 62 2003 205 212
43. B.M. Ross, D.K. Kim, J.V. Bonventre, S.J. Kish Characterization of a novel phospholipase A2 activity in human brain J Neurochem 64 1995 2213 2221
44. B.M. Ross, C. Hudson, J. Erlich, J.J. Warsh, S.J. Kish Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2 Arch Gen Psychiatry 54 1997 487 494
45. B.M. Ross, S. Turenne, A. Moszczynska, J.J. Warsh, S.J. Kish Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia Brain Res 821 1999 407 413
46. J.K. Rybakowski, A. Borkowska, P.M. Czerski, M. Dmitrzak-Weglarz, J. Hauser The study of cytosolic phospholipase A2 gene polymorphism in schizophrenia using eye movement disturbances as an endophenotypic marker Neuropsychobiology 47 2003 115 119
47. A. Sapirstein, R.A. Spech, R. Witzgall, J.V. Bonventre Cytosolic phospholipase A2 (PLA2), but not secretory PLA2, potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells J Biol Chem 271 1996 21505 21513
48. T. Shioiri, T. Kato, T. Inubushi, J. Murashita, S. Takahashi Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia Psychiatry Res 55 1994 223 235
49. T. Shioiri, T. Someya, J. Murashita, T. Kato, H. Hamakawa, K. Fujii, T. Inubushi Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia Psychiatry Res 76 1997 113 122
50. J.A. Stanley, J.W. Pettegrew, M.S. Keshavan Magnetic resonance spectroscopy in schizophrenia Methodological issues and findings--part I Biol Psychiatry 48 2000 357 368
51. J.A. Stanley, P.C. Williamson, D.J. Drost, T.J. Carr, R.J. Rylett, A. Malla, R.T. Thompson An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy Arch Gen Psychiatry 52 1995 399 406
52. J.A. Stanley, P.C. Williamson, D.J. Drost, T.J. Carr, R.J. Rylett, S. Morrison-Stewart, R.T. Thompson Membrane phospholipid metabolism and schizophrenia An in vivo 31P-MR spectroscopy study Schizophr Res 13 1994 209 215
53. M.M. Taketo, S. Masahiro Phospholipase A2 and apoptosis Biochimica et Biophysica Acta 1585 2002 72 76
54. H. Tavares, J. Yacubian, L.L. Talib, N.R. Barbosa, W.F. Gattaz Increased phospholipase A2 activity in schizophrenia with absent response to niacin Schizophr Res 61 2003 1 6
55. T. Thuren, J.A. Virtanen, M. Lalla, P.K. Kinnunen Fluorometric assay for phospholipase A2 in serum Clin Chem 31 1985 714 717
56. H.I. Trzeciak, W. Kalacinski, A. Malecki, D. Kokot Effect of neuroleptics on phospholipase A2 activity in the brain of rats Eur Arch Psychiatry Clin Neurosci 245 1995 179 182
57. H.P. Volz, R. Rzanny, S. May, H. Hegewald, B. Preussler, M. Hajek 31P magnetic resonance spectroscopy in the dorsolateral prefrontal cortex of schizophrenics with a volume selective technique--preliminary findings Biol Psychiatry 41 1997 644 648
58. P. Williamson, D. Drost, J. Stanley, T. Carr, S. Morrison, H. Merskey Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls Arch Gen Psychiatry 48 1991 578
59. H.-U. Wittchen, T. Fydrich, M. Zaudig Strukturiertes Klinisches Interview für DSM-IV 1979 Hogrefe Verlag Göttingen
60. J.K. Yao, R. Reddy, D.P. van Kammen Abnormal age-related changes of plasma antioxidant proteins in schizophrenia Psychiatry Res 97 2000 137 151